MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis

NASDAQ:MLAB • US59064R1095

90.59 USD
+2.02 (+2.28%)
Last: Feb 13, 2026, 08:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to MLAB. MLAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. While MLAB has a great profitability rating, there are quite some concerns on its financial health. MLAB has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year MLAB was profitable.
  • MLAB had a positive operating cash flow in the past year.
  • In multiple years MLAB reported negative net income over the last 5 years.
  • Each year in the past 5 years MLAB had a positive operating cash flow.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.86%, MLAB is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 2.00%, MLAB is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
  • MLAB has a better Return On Invested Capital (3.58%) than 65.52% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 12.42%.
  • The 3 year average ROIC (2.10%) for MLAB is below the current ROIC(3.58%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • With a decent Profit Margin value of 1.51%, MLAB is doing good in the industry, outperforming 68.97% of the companies in the same industry.
  • With a decent Operating Margin value of 6.96%, MLAB is doing good in the industry, outperforming 62.07% of the companies in the same industry.
  • MLAB's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 62.40%, MLAB belongs to the top of the industry, outperforming 82.76% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MLAB has grown nicely.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
  • The number of shares outstanding for MLAB has been increased compared to 1 year ago.
  • MLAB has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MLAB has an improved debt to assets ratio.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • MLAB has an Altman-Z score of 1.47. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of MLAB (1.47) is comparable to the rest of the industry.
  • MLAB has a debt to FCF ratio of 4.41. This is a neutral value as MLAB would need 4.41 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 4.41, MLAB is doing good in the industry, outperforming 70.69% of the companies in the same industry.
  • A Debt/Equity ratio of 0.86 indicates that MLAB is somewhat dependend on debt financing.
  • MLAB has a worse Debt to Equity ratio (0.86) than 79.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.47
ROIC/WACC0.34
WACC10.46%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • MLAB has a Current Ratio of 1.94. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.94, MLAB is not doing good in the industry: 60.34% of the companies in the same industry are doing better.
  • MLAB has a Quick Ratio of 1.45. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • MLAB has a Quick ratio of 1.45. This is in the lower half of the industry: MLAB underperforms 65.52% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for MLAB have decreased strongly by -87.40% in the last year.
  • Measured over the past years, MLAB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -39.16% on average per year.
  • Looking at the last year, MLAB shows a small growth in Revenue. The Revenue has grown by 4.12% in the last year.
  • The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 247.51% yearly.
  • The Revenue is expected to grow by 4.11% on average over the next years.
EPS Next Y2707.43%
EPS Next 2Y380.33%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y3.97%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 141.55 indicates a quite expensive valuation of MLAB.
  • MLAB's Price/Earnings is on the same level as the industry average.
  • When comparing the Price/Earnings ratio of MLAB to the average of the S&P500 Index (27.97), we can say MLAB is valued expensively.
  • The Price/Forward Earnings ratio is 56.09, which means the current valuation is very expensive for MLAB.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, MLAB is valued quite expensively.
Industry RankSector Rank
PE 141.55
Fwd PE 56.09
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100

4.2 Price Multiples

  • MLAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MLAB is cheaper than 84.48% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, MLAB is valued cheaper than 94.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.27
EV/EBITDA 15.08
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MLAB may justify a higher PE ratio.
  • MLAB's earnings are expected to grow with 247.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y380.33%
EPS Next 3Y247.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.72%, MLAB is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.10, MLAB pays a better dividend. On top of this MLAB pays more dividend than 98.28% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.84, MLAB's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.72%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
  • MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 93.97% of the earnings are spent on dividend by MLAB. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y380.33%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MESA LABORATORIES INC

NASDAQ:MLAB (2/13/2026, 8:26:24 PM)

90.59

+2.02 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners92.73%
Inst Owner Change-10.21%
Ins Owners5.44%
Ins Owner Change3.69%
Market Cap500.06M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target100.98 (11.47%)
Short Float %4.73%
Short Ratio2
Dividend
Industry RankSector Rank
Dividend Yield 0.72%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)4.21%
PT rev (3m)11.86%
EPS NQ rev (1m)7.55%
EPS NQ rev (3m)-14.61%
EPS NY rev (1m)0%
EPS NY rev (3m)9.16%
Revenue NQ rev (1m)0.52%
Revenue NQ rev (3m)0.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.4%
Valuation
Industry RankSector Rank
PE 141.55
Fwd PE 56.09
P/S 2.02
P/FCF 13.27
P/OCF 12.04
P/B 2.68
P/tB N/A
EV/EBITDA 15.08
EPS(TTM)0.64
EY0.71%
EPS(NY)1.61
Fwd EY1.78%
FCF(TTM)6.83
FCFY7.54%
OCF(TTM)7.52
OCFY8.31%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.05
PEG (5Y)N/A
Graham Number22.07
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.47
F-Score6
WACC10.46%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y2707.43%
EPS Next 2Y380.33%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year3.09%
Revenue Next 2Y3.97%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year177.2%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


How profitable is MESA LABORATORIES INC (MLAB) stock?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


What is the financial health of MESA LABORATORIES INC (MLAB) stock?

The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 2707.43% in the next year.